These stocks are both experts in their respective fields.
These pharmaceutical companies are top-notch dividend growth stocks for the future.
This is a stock you shouldn't hesitate to buy on the dip.
The anti-obesity medication stock is way up, and there could be more fuel in the tank.
The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop.
The path is clear for even more growth from Novo Nordisk's top two drugs, Ozempic and Wegovy.
NVO earnings call for the period ending March 31, 2024.
Novo Nordisk (NVO), known for its popular weight-loss drug Wegovy, has seen its shares surge by more than 350% since 2020, yet it continues to trade at a 30% discount to its main U.S. competitor, Eli Lilly...
We also look at the "treasure hunt" economy.